{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 41,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/29",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.58,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Avoiding TRK Inhibition",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6fe6031-b53c-4484-81e8-4ea23b9df415",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.15,
        "x": 0.38,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Brain Penetrance",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1830ab2c-0106-43c5-8087-7049a74f8ed4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "In Vitro Activity, ROS1 Wild-type & Mutant",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e29ee91-9823-4a35-944e-83e8ee198a03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26931fb2-0462-4ea7-abaa-defa2471be91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "Preclinical Characterization Demonstrates Desired Target Product Profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9b70d7a-fd8a-4150-980f-d3838fb88515",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}